I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by QuantumLeap Healthcare Collaborative
Sponsor:
Information provided by (Responsible Party):
QuantumLeap Healthcare Collaborative
ClinicalTrials.gov Identifier:
NCT01042379
First received: December 31, 2009
Last updated: July 11, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):